<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sell LB</submitter><funding>NINDS NIH HHS</funding><funding>National Institutes of Health</funding><pagination>108766</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8660955</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>235</volume><pubmed_abstract>Farnesol is a 15‑carbon organic isoprenol synthesized by plants and mammals with anti-oxidant, anti-inflammatory, and neuroprotective activities. We sought to determine whether farnesol treatment would result in protection against murine experimental autoimmune encephalomyelitis (EAE), a well-established model of multiple sclerosis (MS). We compared disease progression and severity in C57BL/6 mice treated orally with 100 mg/kg/day farnesol solubilized in corn oil to corn-oil treated and untreated EAE mice. Farnesol significantly delayed the onset of EAE (by ~2 days) and dramatically decreased disease severity (~80%) compared to controls. Disease protection by farnesol was associated with a significant reduction in spinal cord infiltration by monocytes-macrophages, dendritic cells, CD4&lt;sup></pubmed_abstract><journal>Clinical immunology (Orlando, Fla.)</journal><pubmed_title>Farnesol induces protection against murine CNS inflammatory demyelination and modifies gut microbiome.</pubmed_title><pmcid>PMC8660955</pmcid><funding_grant_id>R15 NS107743</funding_grant_id><pubmed_authors>Doyle WJ</pubmed_authors><pubmed_authors>Ramelow CC</pubmed_authors><pubmed_authors>Gibson KM</pubmed_authors><pubmed_authors>Kohl HM</pubmed_authors><pubmed_authors>Sell LB</pubmed_authors><pubmed_authors>Strawn KD</pubmed_authors><pubmed_authors>Hoffman K</pubmed_authors><pubmed_authors>Ochoa-Reparaz J</pubmed_authors><pubmed_authors>Bains JK</pubmed_authors><pubmed_authors>Kirby TO</pubmed_authors><pubmed_authors>Roullet JB</pubmed_authors><pubmed_authors>Hevrin T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Farnesol induces protection against murine CNS inflammatory demyelination and modifies gut microbiome.</name><description>Farnesol is a 15‑carbon organic isoprenol synthesized by plants and mammals with anti-oxidant, anti-inflammatory, and neuroprotective activities. We sought to determine whether farnesol treatment would result in protection against murine experimental autoimmune encephalomyelitis (EAE), a well-established model of multiple sclerosis (MS). We compared disease progression and severity in C57BL/6 mice treated orally with 100 mg/kg/day farnesol solubilized in corn oil to corn-oil treated and untreated EAE mice. Farnesol significantly delayed the onset of EAE (by ~2 days) and dramatically decreased disease severity (~80%) compared to controls. Disease protection by farnesol was associated with a significant reduction in spinal cord infiltration by monocytes-macrophages, dendritic cells, CD4&lt;sup></description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-19T17:57:52.273Z</modification><creation>2025-04-19T17:57:52.273Z</creation></dates><accession>S-EPMC8660955</accession><cross_references><pubmed>34091018</pubmed><doi>10.1016/j.clim.2021.108766</doi></cross_references></HashMap>